<DOC>
	<DOCNO>NCT02871310</DOCNO>
	<brief_summary>The main objective study evaluate benefit IQP-AS-118 vasoactive effect healthy subject .</brief_summary>
	<brief_title>Vasoactive Effects IQP-AS-118 Healthy Individuals</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>1 . Caucasian male female 4565 year age 2 . Body mass index ( BMI ) 25.029.9 kg/m2 3 . Blood pressure ( BP ) screening : systolic blood pressure ( SBP ) ≤ 140 mmHg diastolic blood pressure ( DBP ) ≤ 90 mmHg 4 . EndoPAT score : ≤ 2.00 ) screen 5 . Generally good health , particular electrocardiogram ( ECG ) without pathological finding screen 6 . Readiness comply study procedure , particular : Consumption investigational product ( IP ) / placebo accord investigator 's advise Maintaining level physical activity usual diet entire study Accepting blood draw Able undergo EndoPAT assessment Complying visit respective requirement BP EndoPAT measurement Filling diaries/questionnaires 7 . Nonsmoker since least 6 month prior screen study 8 . Stable body weight last 3 month prior screen ( &lt; 3 kg selfreported change ) study 9 . Concomitant medication must stable least last 1 month prior screening , applicable 10 . In woman : postmenopausal least 12 month Participation base upon write informed consent form ( ICF ) participant follow write oral information investigator regard nature , purpose , consequence possible risk clinical study . 1 . Known sensitivity component IP 2 . Known primary secondary hypertension whitecoat hypertension 3 . Known impaired endothelial function per investigator 's judgement 4 . Clinically significant disturbance lipid metabolism e.g . know genetic hyperlipidemia 5 . Known type1 / type2diabetes 6 . Untreated nonstabilized thyroid disorder 7 . History and/or presence clinically significant cardiovascular disease per investigator 's judgement : 1 . Known congenital heart defect 2 . Myocardial infarction , heart failure , angina pectoris , lifethreatening arrhythmia stroke within last 6 month prior screen 3 . Existing thrombosis disposition thrombosis 8 . Any known significant serious condition / disease render subject ineligible , e.g . : 1 . History malignancy within ≤5 year prior screen 2 . Bleeding disorder and/or need anticoagulant antiplatelet agent 3 . Current psychiatric care and/or use neuroleptic 4 . Bariatric surgery last 12 month prior screen 9 . Any known metabolic disease , gastrointestinal disorder clinically significant disease/disorder investigator 's opinion could interfere result study safety subject 10 . Known arm lymphedema ( e.g . due mastectomy ) 11 . Other clinically relevant excursion safety parameter clinically significant abnormality hematology and/or biochemistry Investigator 's judgement 12 . Dietary habit and/or restriction may affect study outcome 13 . Eating disorder participation weight loss program 14 . Use medication ( e.g . statin , renin angiotensin system inhibitor , nevibolol , carvedilol , calcium channel blocker ) supplement influence vascular endothelial function and/or blood flow ( e.g . garlic , cocoa ) within last 4 week prior screen study 15 . Use antiplatelet agent / anticoagulant ( e.g . warfarin , acetylsalicylic acid ) within last 4 week prior screen study 16 . Use medication supplement influence SBP DBP ( e.g . ACE inhibitor , diuretic , calcium channel , α ßblockers , grape seed extract , coenzyme Q10 etc . ) within last 4 week prior screen study 17 . Use lipid lower medication ( affect lipid metabolism , platelet function antioxidant status , etc . ) and/or dietary supplement ( e.g . omega3 fatty acid , green tea extract , calcium , red yeast rice , phytosterols ( incl . enrich product e.g . Becel ) , niacin , , glucomannan chitosan ) within last 4 week prior screen study 18 . Use medication influence cholesterol level significantly ( e.g . corticosteroid , amiodarone , estrogen , anabolic steroid ) accord investigator 's judgement 19 . Use weight loss treatment 20 . Alcohol abuse ( men : ≥21 units/week , woman : ≥14 units/ week ; 1 unit equal approximately 250 mL beer , 100 mL wine 35 mL spirit ) 21 . Drug abuse 22 . Reported participation night shift work 2 week prior screen and/or study 23 . Participation another study blood donation last 30 day prior screen study 24 . Any reason deem suitable exclusion per investigator 's judgment , e.g . insufficient compliance study procedure</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>